CureVac (NASDAQ:CVAC) | Finanzwire

Basculer en Français

11221	Companies
248818	Keywords
176608	Articles
134645	Press releases

Home
Companies
CureVac

PRESS RELEASE

published on 11/04/2024 at 13:03, 1 year 11 months ago

CureVac Strengthens Leadership Team with Appointment of Seasoned Industry Executive Axel Sven Malkomes as Chief Financial Officer
CureVac appoints Axel Sven Malkomes as CFO, bringing 30 years of industry experience. His role will drive strategic initiatives, financial foundation, and shareholder value

Biopharmaceutical Company CFO MRNA Technology CureVac Axel Sven Malkomes
PRESS RELEASE

published on 11/04/2024 at 13:00, 1 year 11 months ago

CureVac to Present at the 12th International mRNA Health Conference
CureVac to present new data at the 12th International mRNA Health Conference, showcasing developments in mRNA cancer vaccine and lipid nanoparticle delivery technology

Innovation Biopharmaceutical CureVac MRNA Platform MRNA Health Conference
BRIEF

published on 10/28/2024 at 13:05, 1 year 11 months ago

CureVac to Present New Findings at SITC Annual Meeting

Clinical Trials MRNA Technology Cancer Vaccine CureVac SITC Meeting
PRESS RELEASE

published on 10/28/2024 at 13:00, 1 year 11 months ago

CureVac to Present at the Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting
CureVac to present at Society for Immunotherapy of Cancer (SITC) 39th Annual Meeting, sharing immunogenicity data on mRNA-based cancer vaccine CVGBM. Conference details and contact info provided

CureVac MRNA Poster Presentation Immunogenicity Society For Immunotherapy Of Cancer
BRIEF

published on 09/13/2024 at 14:02, 2 years 1 month ago

CureVac's CVGBM Cancer Vaccine Shows Promising Results in Phase 1 Glioblastoma Study

CureVac Glioblastoma CVGBM Phase 1 Study T-cell Responses
PRESS RELEASE

published on 09/13/2024 at 13:57, 2 years 1 month ago

CureVac’s CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
CureVac's CVGBM Cancer Vaccine induces promising immune responses in Phase 1 Study in Glioblastoma presented at ESMO 2024 Congress. Results show de novo T-cell activity & acceptable safety profile up to 100 µg dose

Cancer Vaccine CureVac CVGBM Phase 1 Study Immune Responses
BRIEF

published on 09/12/2024 at 13:02, 2 years 1 month ago

CureVac and GSK Report Positive Phase 2 Data for Influenza mRNA Vaccine

MRNA Technology Influenza Vaccine Phase 2 Results GSK Partnership CureVac Milestone
PRESS RELEASE

published on 09/12/2024 at 12:57, 2 years 1 month ago

CureVac Partner GSK Announces Positive Phase 2 Data from Seasonal Influenza mRNA Vaccine Program
CureVac Partner GSK reports positive Phase 2 results for seasonal influenza mRNA vaccine program. Data show immune responses to A and B strains with acceptable safety profile

GSK CureVac Phase 2 MRNA Vaccine Seasonal Influenza
BRIEF

published on 09/09/2024 at 13:05, 2 years 1 month ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress

Clinical Data CureVac MRNA Vaccine Glioblastoma ESMO Congress
PRESS RELEASE

published on 09/09/2024 at 13:00, 2 years 1 month ago

CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
CureVac to present first CVGBM Glioblastoma cancer vaccine clinical data at ESMO 2024 Congress. First-in-human study results to be shared, highlighting mRNA technology's potential for cancer vaccines

MRNA Technology CureVac Glioblastoma CVGBM ESMO 2024 Congress

Accesswire

Published on 10/23/2026 at 13:23, 51 minutes ago

Slam Mobilizes Drill Team to Moose Lake, Intersecting Broad Zones of Brecciated and Altered Rock With Visible Stibnite Along the Moose Lake Fault Zone
Published on 10/23/2026 at 13:00, 1 hour 14 minutes ago

First Canadian Graphite Inc. Announces Flow-Through Financing
Published on 10/23/2026 at 02:20, 11 hours 54 minutes ago

Apex Announces Nasdaq Listing and Pricing of US$1.86 Million Offering
Published on 10/22/2026 at 23:30, 14 hours 44 minutes ago

Cypher Announces Subscription Receipt Offering
Published on 10/22/2026 at 22:30, 15 hours 44 minutes ago

Unusual Machines to Announce Third Quarter 2026 Financial Results and Provide Corporate Update

View all ACCESSWIRE

EQS Group

Published on 10/23/2026 at 14:00, 14 minutes ago

Alzchem again ranked among the top 5% of companies rated worldwide by EcoVadis
Published on 10/23/2026 at 13:25, 49 minutes ago

India's Spiritual Leadership Takes Center Stage Globally: *H.H. Shree Shivkrupanand Swami, promoter of global spritual platform 'Gurutattva' and 'Himalayan Samarpan Meditation', appointed Vice Chair of 'World Meditation Day Governance Committee'
Published on 10/23/2026 at 12:54, 1 hour 19 minutes ago

EQS-Adhoc: Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München: Munich Re reports quarterly net profit of €1.7bn and raises full-year guidance
Published on 10/23/2026 at 12:46, 1 hour 27 minutes ago

Cairn Homes Plc: Holding(s) in Company
Published on 10/23/2026 at 12:38, 1 hour 36 minutes ago

Cairn Homes Plc: Holding(s) in Company

Les Echos

Published on 10/23/2026 at 07:00, 7 hours 14 minutes ago

Safran reports third quarter 2026 revenue
Published on 10/22/2026 at 18:00, 20 hours 14 minutes ago

THERMADOR GROUPE : Completion of the share buy-back programme launched in August
Published on 10/22/2026 at 18:00, 20 hours 14 minutes ago

bioMérieux receives Dual 510(k) Clearance and CLIA Waiver from the FDA for the BIOFIRE® SPOTFIRE® Vaginitis Panel to Advance Women’s Health with Rapid Molecular Diagnostics
Published on 10/22/2026 at 18:00, 20 hours 14 minutes ago

H1 2026: marked improvement in operating results
Published on 10/22/2026 at 17:47, 20 hours 27 minutes ago

Aéroports de Paris SA - 2026 9-month revenue

View all LES ECHOS COMFI WIRE